搜索
 > 【Mucin-1】重组蛋白信息

Mucin-1信息

英文名称:Mucin-1
中文名称:黏蛋白-1
靶点别称:Episialin,Polymorphic epithelial mucin,MUC1-alpha,Peanut-reactive urinary mucin,MUC-1,Tumor-associated mucin,MUC1-CT,MUC1-beta,MUC1,Krebs von den Lungen-6,Mucin-1 subunit alpha,Mucin-1 subunit beta,Cancer antigen 15-3,CD_antigen=CD227,Breast carcinoma-ass
上市药物数量:0
临床药物数量:30
最高研发阶段:临床三期

Mucin-1 Molecule Synonym Name

Mucin 1,MUC1,CD227,EMA,H23AG,KL-6,MAM6,MUC-1/SEC,MUC-1/X,MUC1/ZD,PEM,PEMT,PUM,CA 15-3,Episialin

Mucin-1 分子背景

Mucin-1 (MUC1) is also known as Tumor-associated epithelial membrane antigen (EMA), Polymorphic epithelial mucin (PEM), Peanut-reactive urinary mucin (PUM), PEMT, Krebs von den Lungen-6 (KL-6), CD antigen CD227, Episialin, H23AG. MUC1 is a glycoprotein with extensive O-linked glycosylation of its extracellular domain. Mucins line the apical surface of epithelial cells in the lungs, stomach, intestines, eyes and several other organs. Mucins protect the body from infection by pathogen binding to oligosaccharides in the extracellular domain, preventing the pathogen from reaching the cell surface. Except protective function by binding to pathogens, MUC1 also functions in a cell signaling capacity. Overexpression of MUC1 is often associated with colon, breast, ovarian, lung and pancreatic cancers.

Mucin-1 参考文献

Mucin-1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
MUC1-Poly-ICLC MUC1-poly-ICLC,MUC1 poly ICLC 临床二期 University of Pittsburgh 非小细胞肺癌, 结肠直肠癌 详情
Monoclonal antibody SM-3 临床一期 Cancer Research Technology 真性红细胞增多症, 实体瘤
90Y Clivatuzumab Tetraxetan 90Y-hPAM4; 90hY-PAM4; IMMU-107,90YhPAM4; 90hYPAM4; IMMU107 临床三期 Immunomedics 胰腺癌 详情
Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) 临床二期 University of Sydney, 广州安捷生物医学技术有限公司, 广东药科大学附属第一医院 晚期非小细胞肺癌
Cancer vaccine MUC-1 (GlaxoSmithKline/University of Pittsburgh) 临床一期 葛兰素史克, University of Pittsburgh 结肠癌, 乳腺癌, 胰腺癌
Monoclonal Antibody ICO25 (Russian National Cancer Research Center) ICO-25 临床二期 俄罗斯国立癌症研究中心, P Hertzen Moscow Cancer Research Institute 癌症
Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) 临床一期 上海斯丹赛生物技术 乳腺癌, 肺癌, 胰腺癌
Gly-MUC1 conjugate prostate tumor vaccine (Memorial Sloan-Kettering) 临床一期 斯隆-凯特琳癌症中心, Adjuvantys 前列腺癌
GO-2032c GO-203-2C 临床二期 Genus Oncology, Dana-Farber Cancer Institute 急性骨髓性白血病 详情
MUC1-peptide-pulsed dendritic cell vaccine (Fudan University) 临床一期 复旦大学 胰腺癌
huMNC2-CAR44 huMNC2-CAR44 临床一期 Minerva Biotechnologies 乳腺癌 详情
Anti-MUC1 CAR T cell (Guangzhou Anjie Biomedical) 临床二期 广州安捷生物医学技术有限公司 非小细胞肺癌, 前列腺癌, 食道癌
hCTMO1 hCTMO1 临床一期 Celltech 实体瘤
Anti-MUC1 monoclonal antibody (OncoQuest) Anti-MUC1 AR20.5; AR20.5; mAb-AR20.5 临床二期 AltaRex, OncoQuest, ViRexx Medical Corp 乳腺癌, 多发性骨髓瘤, 胰腺癌
MX-DTPA BrE-3 临床一期 Nonindustrial source 乳腺癌
R-1549 临床三期 Cancer Research UK, Antisoma, 罗氏 胃癌, 卵巢癌
Gatipotuzumab GT-MAB-2.5-GEX 临床二期 NEMOD, Glycotope 实体瘤, 卵巢癌 详情
TG-4010 TG-4010; VV-MUC-IL2 临床三期 Transgene 非小细胞肺癌 详情
Breast cancer vaccine BP1 7 (Biomira) 临床一期 Biomira 乳腺癌
IMT 504 IMT-504,IMT504 临床二期 Immunotech 神经痛, 狂犬病, 糖尿病, 慢性淋巴细胞白血病, 乳腺癌, 乙肝, 脓毒症, 流感病毒感染, 骨质疏松症
ONT-10 BGLP-40; L-BGLP40; ONT-10,BGLP40; LBGLP40; ONT10,BGLP 40; LBGLP 40; ONT 10 临床一期 Cascadian Therapeutics 乳腺癌, 实体瘤, 卵巢癌
Adenoviral MUC1 vaccine (Etubics) Ad5 MUC1; ETBX-061 临床二期 Etubics Corporation 尿路上皮癌, 乳腺癌, 头颈部鳞状细胞癌, 实体瘤, 非霍奇金淋巴瘤, 卵巢癌, 结肠癌, 三阴性乳腺癌, 非小细胞肺癌, Merkel细胞癌, 前列腺癌, 结肠直肠癌, 肺癌, 鳞状细胞癌, 黑色素瘤 详情
Anti-PEM monoclonal antibody 临床二期 Access Pharmaceuticals 乳腺癌
Anti-PD-L1/MUC1 CAR-pNK cell therapy (PersonGen Biomedicine/Anke Biotechnology) CAR-pNK (PersonGen Biomedicine/Anke Biotechnology),CAR pNK (PersonGen Biomedicine/Anke Biotechnology) 临床二期 博生吉医药科技有限公司, 安科生物 实体瘤
CMB-401 CMB-401; CDP-671 临床二期 Celltech 非小细胞肺癌, 卵巢癌
Recombinant HSP-MUC1 fusion protein (Newsummit) 临床一期 上海新生源医药 乳腺癌
Activated CIK and CD3-MUC1 bispecific antibody 临床二期 本康生物 乳腺癌, 结肠直肠癌, 肝癌, 胰腺癌 详情
Monoclonal antibody HMFG1 AS-1402; BTH-1704; HuHMFG-1; R-1550 临床一期 Cancer Research UK, Antisoma 胰腺癌 详情
BP1-7-KLH BP1-7-KLH; BLP-16 临床一期 Cascadian Therapeutics 乳腺癌
Pepscan (Antisoma) AS-109 临床二期 Antisoma 乳腺癌

消息提示

请输入您的联系方式,再点击提交!

确定